![A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method | BMC Cancer | Full Text A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5801-3/MediaObjects/12885_2019_5801_Fig1_HTML.png)
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method | BMC Cancer | Full Text
![A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation - ScienceDirect A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169260708000035-gr1.jpg)
A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation - ScienceDirect
![Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority | JCO Precision Oncology Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2019/po.2019.3/po.19.00032/20191023/images/large/po.19.00032t1.jpeg)
Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority | JCO Precision Oncology
![Bertrand Delsuc on Twitter: "Straathof/UCL - clinical trial using a rolling 6 design 14/14=100% manuf success rate product characteristics https://t.co/CamF3tdlCU" / Twitter Bertrand Delsuc on Twitter: "Straathof/UCL - clinical trial using a rolling 6 design 14/14=100% manuf success rate product characteristics https://t.co/CamF3tdlCU" / Twitter](https://pbs.twimg.com/media/Dzbock-W0AAdfeK.jpg)
Bertrand Delsuc on Twitter: "Straathof/UCL - clinical trial using a rolling 6 design 14/14=100% manuf success rate product characteristics https://t.co/CamF3tdlCU" / Twitter
![Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials | Future Drug Discovery Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials | Future Drug Discovery](https://www.future-science.com/cms/10.4155/fdd-2019-0021/asset/images/medium/figure1.gif)
Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials | Future Drug Discovery
![BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. - Abstract - Europe PMC BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8462603/bin/cci-5-cci.20.00122-g001.jpg)